Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
33
CNCR Quote, Financials, Valuation and Earnings
Last price:
$12.35
Seasonality move
:
-4.35%
Day range:
$12.24 - $12.53
52-week range:
$11.87 - $17.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.7K
Avg. volume:
3K
1-year change:
-6.66%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingRange Cancer Therapeutics ETF has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Range Cancer Therapeutics ETF has an estimated downside of -- from its current price of $12.61.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $12.61.
Fair Value
-
According to the consensus of 0 analysts, Range Cancer Therapeutics ETF has -- downside to fair value with a price target of -- per share.
CNCR vs. S&P 500
-
Over the past 5 trading days, Range Cancer Therapeutics ETF has underperformed the S&P 500 by -2.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Range Cancer Therapeutics ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Range Cancer Therapeutics ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Range Cancer Therapeutics ETF reported revenues of --.
Earnings Growth
-
Range Cancer Therapeutics ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Range Cancer Therapeutics ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-27 | 2023-12-27 | 2023-12-27 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-27 | 2021-12-27 | 2022-12-27 | 2023-12-27 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-27 | 2023-12-27 | 2023-12-27 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
CNCR
Sector
Market Cap
--
--
Price % of 52-Week High
70.21%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-6.66%
--
Beta (5-Year)
0.903
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$12.53
200-day SMA
Sell
Level
$14.73
Bollinger Bands (100)
Sell
Level
13.59 - 15.35
Chaikin Money Flow
Buy
Level
982.4K
20-day SMA
Sell
Level
$13.41
Relative Strength Index (RSI14)
Sell
Level
38.59
ADX Line
Buy
Level
13.07
Williams %R
Neutral
Level
-72.3881
50-day SMA
Sell
Level
$14.22
MACD (12, 26)
Sell
Level
-0.54
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
2.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, CNCR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNCR average analyst price target in the past 3 months is --.
-
Where Will Range Cancer Therapeutics ETF Stock Be In 1 Year?
According to analysts, the consensus estimate is that Range Cancer Therapeutics ETF share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Range Cancer Therapeutics ETF?
Analysts are divided on their view about Range Cancer Therapeutics ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Range Cancer Therapeutics ETF is a Sell and believe this share price will rise from its current level to --.
-
What Is Range Cancer Therapeutics ETF's Price Target?
The price target for Range Cancer Therapeutics ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CNCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Range Cancer Therapeutics ETF is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CNCR?
You can purchase shares of Range Cancer Therapeutics ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Range Cancer Therapeutics ETF shares.
-
What Is The Range Cancer Therapeutics ETF Share Price Today?
Range Cancer Therapeutics ETF was last trading at $12.35 per share. This represents the most recent stock quote for Range Cancer Therapeutics ETF. Yesterday, Range Cancer Therapeutics ETF closed at $12.61 per share.
-
How To Buy Range Cancer Therapeutics ETF Stock Online?
In order to purchase Range Cancer Therapeutics ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.22% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 4.72% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.82% over the past day.
